# PT-141 (Bremelanotide / Vyleesi)

**Last Updated:** December 4, 2025
**OCEBM Evidence Level:** 1-2 (Phase III RCTs, FDA approved)
**Risk Profile:** LOW-MODERATE
**FDA Status:** APPROVED (2019)

---

## What Is This?

PT-141 (brand name Vyleesi) is an **FDA-approved** medication for low sexual desire in premenopausal women. Unlike Viagra (which works on blood vessels), PT-141 works in the brain on desire pathways — it makes you want sex, not just able to have it. It's derived from Melanotan but **without the tanning or melanoma risks**. Downside: ~40% experience nausea with first use, and only ~25% are "responders." For men, it's used off-label with some success in those who don't respond to PDE5 inhibitors.

---

## Categories

`Sexual Function`

---

## Glossary

| Term | Meaning |
|------|---------|
| OCEBM | Oxford Centre for Evidence-Based Medicine — rates evidence quality |
| MC4R | Melanocortin 4 Receptor — brain receptor controlling sexual desire |
| HSDD | Hypogonadotropic Sexual Desire Disorder — clinically low libido |
| CNS | Central Nervous System — PT-141 works in the brain, not peripherally |
| PDE5 inhibitors | Viagra, Cialis — drugs that work on blood vessels for erections |
| Responder rate | Percentage who experience meaningful benefit (~25% for PT-141) |
| Hyperpigmentation | Skin darkening — can occur with frequent use (>8 doses/month) |

---

## Key Specifications

| Property | Value |
|----------|-------|
| Brand Name | Vyleesi |
| Type | Melanocortin receptor agonist (MC1R, MC3R, MC4R) |
| Molecular Weight | ~1,025 Da |
| Half-life | ~2.7 hours |
| Administration | Subcutaneous |
| FDA Indication | HSDD in premenopausal women |
| Male Approval | None (off-label use only) |

---

## Mechanism of Action

PT-141 represents a fundamentally different approach to sexual dysfunction than the medications most people know. Where Viagra and similar drugs act on blood vessels to enable erections, PT-141 works in the central nervous system on the melanocortin 4 receptor (MC4R), which sits at the intersection of sexual desire pathways in the hypothalamus and limbic system. This is the brain's desire machinery—the neural circuits that make you want sex in the first place, not just able to have it.

The compound also activates MC1R to a lesser degree and influences dopamine-mediated reward circuits, creating a genuine shift in sexual motivation rather than a mechanical enhancement. This distinction matters profoundly: PT-141 acts on desire itself, making it fundamentally different from vasodilators that only address the physical mechanics of arousal.

---

## Clinical Evidence

The RECONNECT trials established PT-141's efficacy in premenopausal women with hypoactive sexual desire disorder. These Phase III randomised controlled trials demonstrated that women receiving PT-141 showed a 0.6-point increase in desire scores compared to 0.2 points for placebo, with meaningful increases in satisfying sexual events. However, the responder rate tells the real story: approximately 25% of women experience clinically significant benefit, meaning three-quarters see minimal to no effect.

In male populations, Phase II studies revealed erectile improvements, with particular promise in men who don't respond to PDE5 inhibitors like sildenafil. The compound showed efficacy where other treatments had failed, suggesting a different mechanism reaching different populations. Development for male indications was halted in 2007 due to blood pressure concerns with the intranasal formulation, leaving subcutaneous administration as the only studied route—and leaving male use firmly in off-label territory.

What users actually report, when they respond, is increased mental desire and interest rather than forced arousal. The effect is described as "natural desire" returning—easier arousal, improved satisfaction, genuine want rather than mechanical function. For the 75% who don't respond, however, the experience is often one of side effects without benefit, particularly the nausea that affects 40% of first-time users.

---

## Dosing

### FDA-Approved (Women)

| Parameter | Value |
|-----------|-------|
| Dose | 1.75mg SC |
| Timing | 45 minutes before activity |
| Maximum | 1 dose/24 hours |
| Monthly limit | 8 doses |
| Duration limit | Stop after 8 weeks if no improvement |

### Off-Label (Men) — Suggested Titration Ladder

| Step | Dose | Notes |
|------|------|-------|
| Test dose | 0.25–0.5mg SC | Observe for nausea/flushing |
| Functional range | 0.75–1.25mg | 45–90 min before activity |
| Upper ceiling | 2.0mg | Do not exceed |
| Limits | Max 1 dose/24h; max 8 doses/month | Same as female guidelines |

**Nausea Management:**
If significant nausea at a given dose, repeat at 50–75% of that dose next time rather than pre-medicating heavily. Many users find their tolerability improves with lower-dose exposure.

### What Users Actually Experience (Responders)

- Increased mental desire/interest
- Easier arousal and improved satisfaction
- Effects described as "natural desire" rather than "forced"
- Non-responders (~75%) report minimal to no effect

---

## Side Effects

| Effect | Frequency |
|--------|-----------|
| Nausea | ~40% (first injection, often severe) |
| Flushing | ~20% |
| Headache | ~11% |
| Injection site reaction | ~13% |
| Blood pressure increase | Transient (~6 mmHg systolic) |

**Hyperpigmentation:** May occur with >8 doses/month. May not resolve.

---

## Contraindications

- Uncontrolled hypertension
- Cardiovascular disease
- Pregnancy/breastfeeding

---

## Risk Assessment

PT-141 carries a low-to-moderate risk profile, substantially safer than its parent compound Melanotan-2. The primary concern is cardiovascular: the transient blood pressure elevation of approximately 6 mmHg systolic requires screening for uncontrolled hypertension and cardiovascular disease before use. This isn't theoretical—it's why the intranasal formulation development was halted and why current labelling includes cardiovascular contraindications.

The nausea problem affects 40% of users on first injection and can be severe enough to discontinue treatment. This isn't just inconvenient—it represents a real tolerability barrier that limits practical use. The hyperpigmentation risk with frequent use (more than 8 doses monthly) adds another consideration, particularly because it may not resolve after discontinuation.

What PT-141 doesn't carry is the melanoma signal associated with Melanotan-2. The structural modifications that removed tanning effects also removed the most serious long-term risk, making PT-141 the evidence-based choice when sexual effects alone are desired.

The modest efficacy—that 25% responder rate—means most users will experience side effects without benefit. The FDA-mandated discontinuation after 8 weeks without improvement reflects this reality: if you're not responding by then, you won't respond at all.

---

## vs Melanotan-2

| Feature | PT-141 | Melanotan-2 |
|---------|--------|-------------|
| Tanning | No | Yes |
| Sexual effects | Yes | Yes |
| FDA approved | **Yes** | No |
| Melanoma concern | No | **Yes** |
| Nausea | Less severe | More severe |

**For sexual effects alone, PT-141 is the evidence-based choice.**

---

## Synergies and Stacking

PT-141 works through central melanocortin pathways, making it mechanistically distinct from every other sexual function intervention. This creates genuine stacking potential rather than redundancy. Combined with PDE5 inhibitors, PT-141 addresses desire while sildenafil or tadalafil handle vascular function—different mechanisms, complementary effects. For men who respond partially to PDE5 inhibitors (erections possible but desire lacking), the combination may restore both components of sexual function.

The compound doesn't interact significantly with testosterone optimization protocols. In hypogonadal men receiving testosterone replacement, PT-141 adds a desire component that testosterone alone may not fully restore, particularly in men whose low libido persists despite normalised testosterone levels. The mechanisms don't overlap: testosterone provides the hormonal foundation while PT-141 activates the central desire circuitry.

Timing matters for any combination. PT-141 requires 45-90 minutes to take effect, while PDE5 inhibitors work in 30-60 minutes. Taking them together or PT-141 slightly earlier optimises the window where both compounds are active. For testosterone users, PT-141 is used as needed while testosterone provides continuous baseline support.

What doesn't work is combining PT-141 with other melanocortin agonists like Melanotan-2. The mechanisms overlap completely, risks compound, and there's no evidence of additive benefit—only additive side effects.

---

## Use Cases

PT-141 found its clearest application in premenopausal women with hypoactive sexual desire disorder who haven't responded to psychological interventions. This is the FDA-approved indication, supported by Phase III trials, and represents the compound's best evidence base. For these women, particularly those in otherwise healthy relationships where low desire creates distress, PT-141 offers a pharmacological option where few existed.

In male populations, the use case becomes murkier but potentially valuable. Men who don't respond to PDE5 inhibitors—whether due to psychological factors, neurological causes, or unclear reasons—may benefit from PT-141's central mechanism. The Phase II data showed erectile improvements in this specific population, though the lack of FDA approval means this remains off-label territory with all the uncertainty that implies.

The compound has no role in mechanical erectile dysfunction with normal desire, no role in relationship problems masquerading as low libido, and no role in normal sexual function. It treats a specific deficit—low desire with distress—and only works in about 25% of people who have that specific problem. The eight-week trial period recommended by the FDA isn't arbitrary: it's the window to determine if you're a responder or one of the 75% who aren't.

---

## Limitations

1. **Modest efficacy** - ~25% responder rate
2. **High nausea incidence** - May limit use
3. **Not approved for men** - Off-label only
4. **Blood pressure effect** requires monitoring
5. **Cost** - ~$900+ per 4-pack

---

## References

1. Kingsberg SA, et al. Bremelanotide for HSDD: Two Phase 3 Trials. Obstet Gynecol. 2019. (RECONNECT)
2. FDA Approval Letter and Package Insert: Vyleesi. 2019.
3. Bremelanotide. LiverTox - NCBI Bookshelf.
4. Mayo Clinic Drug Information: Bremelanotide.
5. Diamond LE, et al. PT-141 in male ED. Int J Impot Res. 2004.
